Narsimha Reddy Penthala

High Impact

Instructor

University of Arkansas for Medical Sciences

faculty

Pharmaceutics, College of Pharmacy

23 h-index 159 pubs 1,375 cited

Research Areas

Neuroscience and Neuropharmacology Research Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity Studies Mitochondrial Function and Pathology Nanoparticles: synthesis and applications Pharmaceutical Practices and Patient Outcomes Cancer-related molecular mechanisms research Bone health and treatments

Links

ORCID Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Narsimha Reddy Penthala's research focuses on the development and evaluation of novel therapeutic agents and drug delivery systems. His work has investigated the antitumor properties of sesquiterpene lactone analogs as NFκB inhibitors, and the potential of hydroxybenzylamine-deoxyvasicinone hybrids for Alzheimer’s disease. Penthala also studies the aggregation-mediated pathology in neurodegeneration models, examining the effects of thiadiazolidinone (TDZD) analogs on C. elegans lifespan and healthspan.

Additional research areas include the evaluation of bone and kidney toxicity for drug carriers, such as BT2-peg2 for targeted antibiotic delivery. Penthala has also conducted pharmacokinetic studies, including the analysis of morphine-6-O-sulfate in rat plasma and brain. His group investigates the pharmacological dual inhibition of tumor growth and tumor-induced functional limitations in transgenic breast cancer models.

Penthala is an instructor in Pharmaceutics at the University of Arkansas for Medical Sciences, College of Pharmacy. He has published extensively, with a total of 159 publications and 1,375 citations, and holds an h-index of 23. He leads a research group and collaborates with researchers at his institution, including Peter A. Crooks and Meenakshisundaram Balasubramaniam.

Metrics

h-index: 23
Publications: 159
Citations: 1,375

Selected Publications

Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan (2023) DOI
Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer (2023) DOI
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion (2021) DOI
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease (2021) DOI
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD) (2021) DOI
Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone (2021) DOI
A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain (2021) DOI

Grants & Funding

Enhancing the prevention and treatment of orthopaedic infections associated with traumatic injury US Department of Defense Co-Investigator
Development of Small Molecule Radiation Sensitizers NIH/Nat. Cancer Institute - Pass Through: Vanderbilt University Co-Investigator
Development of Novel Therapeutics for Methamphetamine Abuse - Continuation NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Kentucky Research Foundation Co-Investigator
Early Events in Alzheimer Pathogenesis NIH Co-Investigator
Novel melampomagnolide B-based prodrugs for the treatment of leukemia NIH Co-Investigator